Article
Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.
NeuroImage. Clinical - 1 Jan 2020
Regnery Sebastian, Behl Nicolas G R, Platt Tanja, Weinfurtner Nina, Windisch Paul, Deike-Hofmann Katerina, Sahm Felix, Bendszus Martin, Debus Jürgen, Ladd Mark E, Schlemmer Heinz-Peter, Rieken Stefan, Adeberg Sebastian, Paech Daniel
Abstract excerpt
PURPOSE: This prospective clinical trial investigated sodium (23Na) MRI at 7 Tesla (T) field strength as biomarker for tumor extent, isocitrate dehydrogenase (IDH) mutation and O6-methylguanine DNA methyltransferase (MGMT) promotor methylation in glioma patients. METHODS: 28 glioma patients underwent 23Na MRI on a 7T scanner (Siemens Healthcare, Erlangen, Germany) parallel to standard 3T MRI before...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
